Loading
Pharmacology and Obesity Treatment / Diabetes Treatment and Management · Journal article
Signal Transduction and Targeted Therapy · August 14, 2026
Encouraging direction, but not yet definitive.
This Phase II trial demonstrates that VCT220, an oral nonpeptide GLP-1 receptor agonist, achieves dose-dependent weight loss of −5.75% to −9.73% over 16 weeks, significantly superior to placebo (−1.61%), with concurrent improvements in HbA1c, fasting insulin, and blood pressure. Tolerability is consistent with the GLP-1 agonist class, dominated by mild-to-moderate gastrointestinal events during titration. These results support progression to Phase III but do not yet establish clinical practice benefit, as the trial is short-term, single-centre evidence remains unavailable by geography, and long-term cardiometabolic outcomes are not yet reported.
Multicenter, randomized, double-blind, placebo-controlled Phase II trial. Adults aged 18–75 years with overweight (BMI 24–28 kg/m² plus ≥1 comorbidity) or obesity (BMI ≥28 kg/m²) enrolled at 13 sites. Intervention: Once-daily oral VCT220 (nonpeptide GLP-1 receptor agonist) at 80 mg, 120 mg, or 160 mg with slow or fast titration, plus lifestyle counselling. Compared with: Placebo plus lifestyle counselling. n = 250. 13 sites in China.
Mean body weight reduction at week 16: −5.75% (80 mg) to −9.73% (160 mg-FT) versus −1.61% placebo (all p < 0.001) Proportion achieving ≥5% weight loss: 55.4% (80 mg) to 90.3% (160 mg-ST) versus 13.1% placebo Improvements in HbA1c, fasting insulin, and blood pressure observed with VCT220
Short follow-up duration (16 weeks) does not assess weight loss sustainability or long-term safety Phase II trial with modest sample size; efficacy and safety require Phase III confirmation
These results are encouraging for development of an oral GLP-1 agonist for obesity but should not yet change practice. Clinicians should await Phase III data on long-term efficacy, durability of weight loss, and cardiometabolic hard outcomes before considering VCT220 as an alternative to existing agents.
Phase II RCT with clear dose-dependent weight loss versus placebo and metabolic benefits, but limited to 16 weeks and requiring Phase III confirmation before clinical adoption.
As stated by the source record.
Quoted from the source exactly as published.
These results are encouraging for development of an oral GLP-1 agonist for obesity but should not yet change practice. Clinicians should await Phase III data on long-term efficacy, durability of weight loss, and cardiometabolic hard outcomes before considering VCT220 as an alternative to existing agents.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract VCT220 is a novel nonpeptide, orally available glucagon-like peptide-1 receptor agonist (GLP-1RA) designed to reduce the complex administration of injectable GLP-1RAs and the limited bioavailability of on-marketing oral agents for obesity care. We conducted a multicenter, randomized, double-blind, placebo-controlled, phase II trial (Registration no. CTR20233978 and NCT06569355) across 13 sites in China. Adults aged 18–75 years with overweight (BMI 24-28 kg/m² plus ≥ 1 comorbidity) or obesity (BMI ≥ 28 kg/m²) were randomly assigned (3:1) to receive once-daily VCT220 (80 mg, 120 mg, or 160 mg with slow or fast titration) or placebo for 16 weeks, alongside lifestyle counselling. The primary endpoint was the percentage change in body weight from baseline to week 16. Two-hundred and fifty participants were randomized (61 to placebo, 189 to VCT220). At week 16, mean body weight decreased by −5.75% (80 mg) to −9.73% (160 mg-FT) versus −1.61% with placebo (all p < 0.001). The proportion achieving ≥5% weight loss ranged from 55.4% (80 mg) to 90.3% (160 mg-ST) with VCT220 versus 13.1% with placebo. VCT220 also improved HbA1c, fasting insulin, and blood pressure. Adverse events were mainly mild-to-moderate gastrointestinal events, most common during titration, and rarely led to discontinuation. VCT220, a once-daily oral nonpeptide GLP-1RA, produced rapid and clinically meaningful weight loss with metabolic benefits over 16 weeks, showing a tolerability profile consistent with the class. These findings support further global phase III evaluation to further verify the efficacy and safety of VCT220 as well as potential cardiometabolic benefits.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.